Russell Investments Group Ltd. Invests $2.14 Million in Cytokinetics, Incorporated (CYTK)

Russell Investments Group Ltd. acquired a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK) during the first quarter, Holdings Channel reports. The fund acquired 166,329 shares of the biopharmaceutical company’s stock, valued at approximately $2,137,000. Russell Investments Group Ltd. owned 0.40% of Cytokinetics, at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Acadian Asset Management LLC bought a new position in Cytokinetics, during the first quarter valued at $4,302,000. FMR LLC boosted its position in Cytokinetics, by 2.7% in the fourth quarter. FMR LLC now owns 5,199,414 shares of the biopharmaceutical company’s stock valued at $63,173,000 after buying an additional 136,758 shares during the period. Norges Bank bought a new position in Cytokinetics, during the fourth quarter valued at $976,000. Shell Asset Management Co. bought a new position in Cytokinetics, during the first quarter valued at $551,000. Finally, A.R.T. Advisors LLC bought a new position in Cytokinetics, during the fourth quarter valued at $394,000. Hedge funds and other institutional investors own 58.47% of the company’s stock.

Institutional Ownership by Quarter for Cytokinetics, (NASDAQ:CYTK)

Cytokinetics, Incorporated (NASDAQ:CYTK) opened at 13.60 on Friday. The firm has a market cap of $613.13 million, a price-to-earnings ratio of 183.78 and a beta of 1.70. Cytokinetics, Incorporated has a one year low of $8.06 and a one year high of $17.20. The stock has a 50 day moving average of $14.39 and a 200 day moving average of $12.56.

WARNING: “Russell Investments Group Ltd. Invests $2.14 Million in Cytokinetics, Incorporated (CYTK)” was first posted by WKRB News and is owned by of WKRB News. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.wkrb13.com/markets/2229561/russell-investments-group-ltd-invests-2-14-million-in-cytokinetics-incorporated-cytk.html.

CYTK has been the subject of several recent research reports. HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of Cytokinetics, in a research report on Tuesday, April 25th. Rodman & Renshaw reiterated a “buy” rating and set a $25.00 target price on shares of Cytokinetics, in a research report on Thursday, March 23rd. Zacks Investment Research cut shares of Cytokinetics, from a “hold” rating to a “strong sell” rating in a research report on Thursday, May 4th. Cowen and Company reiterated an “outperform” rating and set a $19.00 target price (up previously from $17.00) on shares of Cytokinetics, in a research report on Saturday, April 29th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Cytokinetics, in a research report on Friday, May 19th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $20.30.

In related news, CEO Robert I. Blum sold 5,000 shares of Cytokinetics, stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $13.62, for a total transaction of $68,100.00. Following the completion of the transaction, the chief executive officer now owns 94,785 shares of the company’s stock, valued at $1,290,971.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 7.20% of the stock is owned by company insiders.

About Cytokinetics,

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Want to see what other hedge funds are holding CYTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cytokinetics, Incorporated (NASDAQ:CYTK).

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2229561/russell-investments-group-ltd-invests-2-14-million-in-cytokinetics-incorporated-cytk.html

Receive News & Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.